Oxadiazolines as Photoreleasable Labels for Drug Target Identification.


Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
17 Sep 2024
Historique:
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 17 9 2024
Statut: aheadofprint

Résumé

Photoaffinity labeling is a widely used technique for studying ligand-protein and protein-protein interactions. Traditional photoaffinity labels utilize nonspecific C-H bond insertion reactions mediated by a highly reactive intermediate. Despite being the most widely used photoaffinity labels, diazirines exhibit limited compatibility with downstream organic reactions and suffer from storage stability concerns. This study introduces oxadiazolines as innovative and complementary photoactivatable labels for addition to the toolbox and demonstrates their application in vitro and through

Identifiants

pubmed: 39288302
doi: 10.1021/jacs.4c06936
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Corentin Bon (C)

Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.

Benedikt Goretzki (B)

Discovery Sciences, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.

Marie Flamme (M)

Chemical and Analytical Development, Novartis Development, Novartis Pharma AG, Basel 4056, Switzerland.

Claude Shelton (C)

Discovery Sciences, Novartis Biomedical Research, Novartis Pharma AG, Cambridge, Massachusetts 02139, United States.

Holly Davis (H)

Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.

Fabio Lima (F)

Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.

Francisco Garcia (F)

Discovery Sciences, Novartis Biomedical Research, Novartis Pharma AG, Cambridge, Massachusetts 02139, United States.

Scott Brittain (S)

Discovery Sciences, Novartis Biomedical Research, Novartis Pharma AG, Cambridge, Massachusetts 02139, United States.

Cara E Brocklehurst (CE)

Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.

Classifications MeSH